HC Wainwright Reaffirms “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $3.00 target price on the stock.

TransCode Therapeutics Price Performance

Shares of RNAZ opened at $0.34 on Friday. TransCode Therapeutics has a one year low of $0.22 and a one year high of $18.66. The stock’s fifty day moving average is $0.49 and its 200-day moving average is $0.69.

TransCode Therapeutics (NASDAQ:RNAZ) last released its earnings results on Wednesday, August 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.16). Research analysts anticipate that TransCode Therapeutics will post -2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management grew its position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the SEC.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.